However, graft failure and graft-versus-host disease (GVHD) are major causes of the early morbidity in Allo-HSCT.<h4>Methods</h4>To reduce graft failure and GVHD, we treated fifteen patients with SAA using high- dose of HSCT with both G-CSF mobilized PB and BMSCs from HLA-identical siblings to treat patients with SAA.<h4>Results</h4>All patients had successful bone marrow engraftment. The gene discussed is CSF3; the disease is graft versus host disease.